Cargando…
MV140 mucosal bacterial vaccine improves uropathogenic E. coli clearance in an experimental model of urinary tract infection
MV140 is a mucosal vaccine of inactivated whole bacteria (E. coli, K. pneumoniae, E. faecalis, P. vulgaris) with clinical efficacy against recurrent urinary tract infections (UTIs). Here, MV140 was evaluated in a murine model of acute uropathogenic E. coli (UPEC)-induced UTI using the UTI89 strain....
Autores principales: | Saz-Leal, Paula, Ligon, Marianne M., Diez-Rivero, Carmen M., García-Ayuso, Diego, Mohanty, Soumitra, Conejero, Laura, Brauner, Annelie, Subiza, José L., Mysorekar, Indira U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275044/ https://www.ncbi.nlm.nih.gov/pubmed/37333312 http://dx.doi.org/10.21203/rs.3.rs-2992611/v1 |
Ejemplares similares
-
Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
por: Nieto, Antonio, et al.
Publicado: (2021) -
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
por: Brandi, Paola, et al.
Publicado: (2022) -
A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections
por: Martin-Cruz, Leticia, et al.
Publicado: (2021) -
ATG16L1 deficiency in macrophages drives clearance of Uropathogenic E. coli in an IL-1β dependent manner
por: Symington, Jane W., et al.
Publicado: (2015) -
Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections
por: Martín-Cruz, Leticia, et al.
Publicado: (2022)